Nome Bio

What Nome Bio does

Nome Bio (legal entity Nome Therapeutics Inc.) is a Delaware-incorporated, San Diego-based services company that develops and coordinates personalized genetic therapies for patients with rare inherited diseases. The company operates an AI platform combined with human expert review that evaluates a patient's specific genetic mutation against every available therapeutic modality in parallel — antisense oligonucleotides, gene therapy, gene editing, and drug repurposing — to identify the fastest viable path to a custom treatment. Core product offerings include a free Initial Assessment Report (AI-generated, expert-reviewed), a Provider Brief for clinicians with an interrogable chat interface, and an Action Plan covering execution-ready next steps.

Underlying technology includes a multi-modality parallel evaluation engine, generative AI models trained on prior INDs, FDA guidance, and IRB precedent that produce first-draft regulatory submissions with citations, and an AI-driven program orchestration layer coordinating work across 30+ pre-contracted fee-for-service vendors (CROs, CDMOs, manufacturers, regulatory consultants). All work product and IP are structured to remain with the patient family or foundation from day one.

The revenue model is freemium at the top of funnel (free initial genetic assessment) converting into fee-for-service multi-year therapeutic development programs priced per engagement, with no royalties or equity taken from families. Distribution is hybrid: a self-serve digital intake (Typeform) for patients, a gated HIPAA-compliant Provider Platform for clinicians, and referral partnerships with patient advocacy foundations. The company serves rare disease patients and families (primary), clinicians at academic medical centers, research labs and patient foundations, and pharmaceutical companies seeking validation of platform treatment opportunities. Operations are currently domestic-only (United States).

Name

Nome Bio

Legal name

Nome Therapeutics Inc.

Website

https://www.nome.bio

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Nome Bio operates an AI platform with human expert review that develops and coordinates personalized genetic therapies for rare disease patients, families, and clinicians across ASO, gene therapy, gene editing, and drug repurposing modalities.

Ownership category

akta.pro rank

Product category

Personalized Genetic Medicine Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Personalized genetic therapy
• Rare disease therapeutics
• Genetic medicine development
• N-of-1 therapies
• AI drug development

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Free Initial Genetic Assessment: Nome provides a free initial evaluation report analyzing whether a personalized genetic therapy might be appropriate for the patient's specific mutation. This drives top-of-funnel engagement and qualification.
2. Fee-for-Service Therapeutic Development Programs: For families and organizations that proceed after the free evaluation, Nome charges transparent fees for developing comprehensive therapeutic plans and managing the full development process, including selecting partners, coordinating manufacturing, and navigating FDA pathways. The service is priced as a fee-for-service model with no royalties or equity taken from families, and IP is held by the patient/family from day zero.
3. Provider Platform Access: Clinicians register and access the platform to receive Provider Briefs for their patients. While the initial evaluation is free for patients, clinicians at health systems may pay for platform access or the service is structured as a referral/coordinated care model.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Nome provides genetic medicine development as a service for rare disease families, patient foundations, and health systems. Using an AI platform combined with human expert review, the company delivers a free Initial Assessment Report evaluating personalized therapy options for a patient's specific mutation, a clinician-facing Provider Brief with mechanism-level rationale, and end-to-end Therapeutic Development Programs that coordinate 30+ vendors across the full lifecycle from diagnosis through FDA pathways to clinical execution. Programs are structured as fee-for-service with no royalties or equity taken from families, and IP is held by the patient or family from day one.

Product overview

Nome is a services company operating the Operating System for Personalized Therapeutics™ — a unified platform combining an AI analysis engine with human expert oversight. The core offering includes an Initial Assessment Report (AI-generated, expert-reviewed free evaluation of therapy options), a Provider Brief (prioritized options with citations for clinicians), and an Action Plan (detailed execution steps). The platform serves rare disease patients, foundations, health systems, and clinicians by coordinating the full lifecycle of therapeutic development across multiple modalities including gene therapy, ASO therapy, and gene editing.

Differentiator

Problem solved

Functional benefit

Products and services

• Personalized Therapy Development Program End-to-end fee-for-service engagement in which Nome's AI platform and human experts evaluate a patient's specific mutation across multiple therapeutic modalities (ASO, gene therapy, gene editing, drug repurposing), select the fastest viable path, and coordinate 30+ vetted vendors (manufacturers, CROs, CDMOs, regulatory consultants) to develop and deliver a personalized therapy. Programs are priced transparently with no royalties or equity taken from families; all IP is held by the patient or family entity from day one. A comprehensive therapeutic plan is developed within 30 days of the initial assessment.
• Provider Platform (HIPAA-Compliant Clinician Portal) Secure, gated web platform for clinicians at academic medical centers, geneticists, and rare disease specialists to submit patient genetic data under a HIPAA Business Associate Agreement and receive a prioritized Provider Brief with mechanism-level rationale, peer-reviewed citations, and an interrogable chat interface to explore how recommendations were generated.
• Initial Genetic Assessment Report Free initial evaluation service for rare disease patients and families. After submitting a genetic diagnosis through Nome's online intake (Typeform), recipients receive an AI-generated, expert-reviewed report within 1-2 weeks assessing whether a personalized genetic therapy may be appropriate for their specific mutation across multiple modalities. No cost and no obligation to proceed.

Quantifiable outcome

• Free initial evaluation delivered within 1-2 weeks of receiving genetic diagnosis
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• COMBINEDBraincoreStrategic or Co-development PartnerCOMBINEDBrain is a nonprofit consortium representing 65+ rare genetic neurodevelopmental disorder advocacy groups, operating a centralized biorepository in partnership with IBX. Nome works with COMBINEDBrain's biorepository network to ensure patient samples are banked, tracked, and available for downstream therapeutic development. The partnership enables patient cell banking logistics as part of Nome's program management.
• 30+ Fee-for-Service VendorscoreOthersNome operates a network of more than 30 fee-for-service vendors including contract manufacturers, CROs, CDMOs, analytics providers, and regulatory consultants. All contracts are structured fee-for-service with right of reference and escrow provisions, ensuring families/patient entities own all work product and can switch operators without regulatory restart.
• Kizuna FoundationcoreStrategic or Co-development PartnerThe founder Stevie Ringel founded the Kizuna Foundation (a 501(c)(3)) to develop a novel gene therapy for his own rare retinal disease before starting Nome. The foundation's work informs Nome's model and the KIZ-mutation retinitis pigmentosa gene therapy program represents an early proof case for Nome's evaluation approach.
• N=1 CollaborativeminorStrategic or Co-development PartnerWinston Yan, President of the N=1 Collaborative, serves as an advisor to Nome. The N=1 Collaborative (past 2,000 members) is a key organization advancing individualized ASO and gene therapy. This advisory relationship connects Nome to the broader N-of-1 therapy ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Tempus AI: AI-powered precision medicine company with extensive multimodal data, sequencing, and clinical decision support capabilities. Overlapping AI-health positioning with much broader scale and enterprise contracts across pharma and providers.
• GeneDx: Clinical genomics company focused on rare disease diagnosis and whole exome/genome sequencing. Operates upstream of Nome's workflow — feeds the genetic diagnoses that create Nome's customer pipeline — and represents a potential strategic partner or channel.
• Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to identify treatments across multiple disease areas. Comparable AI-for-drug-discovery positioning, but operates a broad pipeline model rather than individualized therapy services.
• Charles River Laboratories: Large CRO/CDMO providing preclinical, clinical, and manufacturing services to the rare disease and broader biotech market. Comparable as one of the vendor types Nome orchestrates; could plausibly build or acquire an n-of-1 coordination layer.
• Deep Genomics: AI-driven RNA therapeutics company using machine learning to identify novel genetic medicines. Comparable AI + genetic medicine positioning, but a pipeline-based biotech rather than a service platform; an advisor (former SVP Research Operations) previously worked there.

Emerging players

• Dyno Therapeutics: AI company designing AAV capsid delivery vectors for gene therapy, including brain-targeting variants. Referenced in Nome's content; operates as a delivery-technology enabler that could integrate into Nome-coordinated programs.
• Creyon Bio: AI-driven oligonucleotide therapeutics company engineering ASOs and siRNAs with safety/efficacy predictively modeled. Comparable AI + genetic medicine focus at the modality level; could be a vendor or partner within Nome's ecosystem.

Direct peers

• COMBINEDBrain: Nonprofit consortium representing 65+ rare genetic neurodevelopmental disorder advocacy groups and operating a centralized biorepository. Both strategic partner and peer — overlapping patient access mission in the rare pediatric neurodevelopmental space, with biorepository and cell-banking infrastructure Nome relies on.
• N=1 Collaborative: Mission-driven organization advancing individualized ASO and gene therapy development, with 2,000+ members across the n-of-1 ecosystem. Directly comparable mission; an advisor to Nome sits on its leadership. Operates as a community/research consortium rather than a commercial service.
• n-Lorem Foundation: Nonprofit providing individualized antisense oligonucleotide (ASO) therapies to patients with ultra-rare genetic diseases at no cost. Most direct peer — also a free, individualized genetic therapy access program for n-of-1 patients, though non-commercial and ASO-only versus Nome's multi-modality commercial model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubenome.bio/solving-rare

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nome Bio